Valiant Laboratories: Q2 FY26 Rights Issue funds utilization compliant, no deviations found
Valiant Laboratories' Monitoring Agency Report for Q2 FY26 confirms appropriate utilization of ₹8,146.88 Lakhs from its Rights Issue, with no deviations from stated objects.
This is a routine regulatory filing confirming compliance regarding the utilization of Rights Issue proceeds. No deviations were reported, which is positive for governance but unlikely to have a high impact on the stock price.
The report confirms that the funds raised through the Rights Issue for the quarter ended September 30, 2025, have been utilized appropriately with no deviations, indicating compliance with regulations but not providing new positive or negative operational news.
* Valiant Laboratories Limited submitted its Monitoring Agency Report for the quarter ended September 30, 2025, concerning the utilization of funds from its Rights Issue. * The report, issued by India Ratings and Research Private Limited, confirmed that the proceeds from the Rights Issue have been utilized appropriately for the objects mentioned in the offer document, with no deviations observed. * The statement was reviewed by the Audit Committee and Board of Directors at their meeting held on November 11, 2025. * The Rights Issue, with a Letter of Offer dated July 15, 2025, had an issue period from July 28, 2025, to August 08, 2025. * The issue comprised 1,08,62,500 equity shares of ₹10 each at ₹75 per share, totaling an issue size of ₹8,146.88 Lakhs. * As of September 30, 2025, ₹7,723.65 Lakhs of the Rights Issue proceeds have been utilized, leaving ₹423.23 Lakhs unutilized. * Key utilization included: * Adjustment of unsecured loans of Promoter/Promoter group: ₹5,800.51 Lakhs * Repayment of outstanding loans of existing promoters Dhanvallabh Ventures LLP: ₹139.51 Lakhs * Capital Expenditure: ₹28.54 Lakhs * General Corporate Purposes: ₹1,710.72 Lakhs * Issue Related Expenses: ₹44.37 Lakhs * The unutilized amount of ₹423.23 Lakhs includes ₹370.00 Lakhs invested in a Fixed Deposit with HSBC Bank (maturing October 18, 2025) and ₹55.52 Lakhs in a bank account, plus ₹2.29 Lakhs interest on FD. * Utilization under General Corporate Purpose included vendor payments (₹1,551.43 Lakhs, with ₹880.83 Lakhs paid to Valiant Organics Limited for raw materials), electricity payments (₹89.57 Lakhs), salary payments (₹33.28 Lakhs), and other miscellaneous expenses (₹36.44 Lakhs).
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.